tazarotene (Tazorac)

a topical acetylenic retinoid; a topical kerytolytic
Also Known As:
Tazorac; AGN 190168; AGN-190168; ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester
Networked: 239 relevant articles (65 outcomes, 66 trials/studies) for this Drug, Comments

Relationship Network

Drug Context: Research Results


1. Chimenti, Sergio: 7 articles (01/2015 - 01/2004)
2. Tanghetti, Emil: 7 articles (03/2013 - 06/2004)
3. Sefton, John: 5 articles (02/2005 - 11/2002)
4. Leyden, James J: 5 articles (02/2005 - 02/2002)
5. Sefton, J: 5 articles (12/2004 - 10/2000)
6. Epstein, Ervin H: 4 articles (04/2014 - 07/2004)
7. Shalita, Alan: 4 articles (05/2010 - 10/2004)
8. Tan, Sheng-shun: 4 articles (02/2009 - 08/2005)
9. Peris, Ketty: 4 articles (01/2006 - 01/2004)
10. Walker, Patricia S: 4 articles (02/2005 - 11/2002)

Related Diseases

1. Psoriasis (Pustulosis Palmaris et Plantaris)
2. Acne Vulgaris
3. Hyperpigmentation
01/01/2006 - "Once-daily application of tazarotene cream was shown to be effective against PIH, achieving significantly greater reductions compared with vehicle in overall disease severity and in the intensity and area of hyperpigmentation within 18 weeks (P< or =.05). "
11/01/2002 - "Compared with the vehicle, at week 24 tazarotene resulted in a significantly greater incidence of patients achieving treatment success (>or=50% global improvement) and at least a 1-grade improvement in fine wrinkling, mottled hyperpigmentation, lentigines, elastosis, pore size, irregular depigmentation, tactile roughness, coarse wrinkling, and the overall integrated assessment of photodamage (P<.01). "
12/01/2004 - "In this multicentre, double-blind, randomized, vehicle-controlled study, 50 patients with photodamaged facial skin (at least mild fine wrinkling and mottled hyperpigmentation, with at least one of these being moderate) were randomized to apply tazarotene 0.1% cream or vehicle cream to their face, once daily for 24 weeks. "
06/01/2004 - "All significant between-group differences in efficacy measures were in favor of tazarotene - for fine wrinkling at the study endpoint and, at earlier timepoints, for treatment success (> or =50% global improvement), and the overall integrated assessment of photodamage, mottled hyperpigmentation, and coarse wrinkling. "
02/01/2005 - "Tazarotene cream was significantly more effective than vehicle in reducing fine wrinkles, mottled hyperpigmentation, lentigines, irregular depigmentation, apparent pore size, elastosis, tactile roughness, and an overall integrated assessment of photodamage. "
Order ALL the reference details at left...
4. Erythema
5. Ichthyosis (Xeroderma)

Related Drugs and Biologics

1. Retinoids
2. calcipotriene (calcipotriol)
3. tazarotene (Tazorac)
4. Tretinoin (Retinoic Acid)
5. adapalene (Differin)
6. Gels
7. Clobetasol (Clobetasol Propionate)
8. Benzoyl Peroxide
9. Dapsone
10. Retinoic Acid Receptors (Retinoic Acid Receptor)

Related Therapies and Procedures

1. Aftercare (After-Treatment)
2. Microspheres (Microsphere)
3. Dye Lasers
4. Phototherapy (Light Therapy)
5. PUVA Therapy

blog comments powered by Disqus
for Psoriasis,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.
  • Free Updates for 1 Year
  • All 2048 Outcomes
  • Top 200 Key Drugs and Biologics
  • Top 50 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Evidence References
  • Sample PDF Report on Psoriasis >>
Price:$24.95 USD & Delivery via PDF download
updates for 1 year
Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:
Price:$490.00 USD access via web interface
1 year subscription
Request Bulk Institution License Details >>